Achievements and challenges of the Sakigake designation system in Japan.
Saved in:
| Title: | Achievements and challenges of the Sakigake designation system in Japan. |
|---|---|
| Authors: | Tanaka M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Idei M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Sakaguchi H; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Kato R; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Sato D; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Sawanobori K; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Kawarasaki S; Office of New Drug 2, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Hata T; Office of New Drug 3, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Yoshizaki A; Office of New Drug 4, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Nakamura M; Office of New Drug 5, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Ikuma M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. |
| Source: | British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Oct; Vol. 87 (10), pp. 4027-4035. Date of Electronic Publication: 2021 Mar 22. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
